CG Oncology Share Holder Equity 2023-2025 | CGON

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

CG Oncology share holder equity from 2023 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

CG Oncology share holder equity from 2023 to 2025. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.1B
Amgen (AMGN)	$157.3B
Gilead Sciences (GILD)	$135.7B
Vertex Pharmaceuticals (VRTX)	$119.2B
Bristol Myers Squibb (BMY)	$94.5B
CSL (CSLLY)	$78.8B
GSK (GSK)	$77.4B
Regeneron Pharmaceuticals (REGN)	$59.2B
Alnylam Pharmaceuticals (ALNY)	$40.6B
Argenex SE (ARGX)	$34B
BioNTech SE (BNTX)	$26.6B
Royalty Pharma (RPRX)	$20.5B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$15.4B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.6B
Incyte (INCY)	$13.2B
Moderna (MRNA)	$12.2B
Exelixis (EXEL)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
Ascendis Pharma (ASND)	$10.7B
QIAGEN (QGEN)	$10.5B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.4B
Bio-Techne Corp (TECH)	$8.1B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.3B